Cubist Submits CTA to Dutch Competent Authority and Ethics Committee to Initiate First-in-Human Study of CB-618
January 10, 2014 at 11:08 AM EST
Cubist Pharmaceuticals (NASDAQ: CBST ) today announced that it submitted a Clinical Trial Application (CTA) to the Dutch Competent Authority and Ethics Committee to initiate a first-in-human study